雷帕鸣适用于什么病症？

What diseases is Rapamin suitable for? The indications for sirolimus include kidney transplants, rare lung diseases, and lymphangioleiomyomatosis (LAM) patients.

Sirolimus inhibits the activation and proliferation of T lymphocytes stimulated by antigens and cytokines (interleukins IL-2, IL-4 and IL-15). It also inhibits the production of antibodies. In cells, sirolimus binds to the immunophilin, FK-binding protein-12 (FKBP-12), to generate the FKBP-12 immunosuppressive complex. This complex binds to the mammalian sirolimus BA molecule and inhibits its activity, thereby inhibiting the progression from G1 to S phase in the cell cycle.

Sirolimus is a lipophilic triene nitrogen-containing macrolide antibiotic compound produced by Streptomyces hygroscopicus isolated from soil samples of Easier Island in the Pacific in 1975 by Vezina and others at Ayerst Laboratory in Canada. Initially used as an antifungal drug with low toxicity, it was found to have immunosuppressive effects in 1977. In 1989, RAPA began to be tried out as a new drug to treat rejection of organ transplants. It is a new immunosuppressant with good efficacy, low toxicity and no nephrotoxicity.

Compared with cyclosporine, rapamycin (sirolimus tablets) oral solution has a smaller dose (only 2 to 3 mg per dose), stronger anti-rejection effect, and fewer side effects. Therefore, since its launch, rapamycin has quickly become a commonly used oral immunosuppressant for organ transplant recipients around the world (especially kidney transplants). Rapamin is a serine/threonine kinase regulated by phosphoinositide-3-kinase and an mTOR (mammalian target of rapamycin) inhibitor. mTOR is a protein that controls many cellular processes, including angiogenesis and cell synthesis, making it a reasonable target for inhibiting severe vascular tumors.